INVO Fertility, Inc. announced an agreement on August 21, 2025, to exchange and amend convertible debentures, reducing the principal by $1.3 million to $1.75 million, along with issuing 325 shares of Series C-2 Preferred Stock to the creditor. This filing is significant and has a neutral sentiment from an investor perspective.